Rachel Brough
Overview
Explore the profile of Rachel Brough including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
4699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitchell J, OLoghlen J, Bray E, McLennan V, McLeod B, Brough R, et al.
Disabil Rehabil Assist Technol
. 2025 Mar;
:1-20.
PMID: 40062596
Assistive technology (AT) can improve functional and technical capacity in the context of work for people with spinal cord injury/damage (SCI/D). This metasynthesis aimed to explore how AT is used...
2.
Bray E, Brough R, Jones R, Burridge L, Geraghty T, Mitchell J, et al.
Disabil Rehabil
. 2025 Mar;
:1-13.
PMID: 40059307
Purpose: The transition from hospital to the community following spinal cord injury (SCI) is a significant and challenging time. Rehabilitation aims to equip individuals with the skills and resources required...
3.
Haider S, Brough R, Madera S, Iacovacci J, Gulati A, Wicks A, et al.
Nat Genet
. 2025 Mar;
57(3):522-529.
PMID: 40033056
To maintain cell fitness, deleterious genetic alterations are buffered by compensatory changes in additional genes. In cancer, buffering processes could be targeted by synthetic lethality. However, despite the large-scale identification...
4.
Dey A, Brough R, Bugg J
Q J Exp Psychol (Hove)
. 2025 Feb;
:17470218251325249.
PMID: 39981671
Learning-guided reactive control is the flexible biasing of attention that is triggered by external cues, such that more focused control settings are retrieved and executed in response to cues predicting...
5.
Stewart J, Krastev D, Brough R, Zatreanu D, Song F, Baxter J, et al.
Oncogene
. 2025 Feb;
44(9):618-629.
PMID: 39939726
Identification of ARID1A/ATR synthetic lethality led to ATR inhibitor phase II trials in ovarian clear cell carcinoma (OCCC), a cancer of unmet need. Using multiple CRISPR-Cas9 mutagenesis and interference screens,...
6.
Kawai-Kawachi A, Lenormand M, Astier C, Herbel N, Cutrona M, Ngo C, et al.
Cancer Res
. 2024 Oct;
85(1):154-170.
PMID: 39412947
Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma subtype that is driven by the EWS-WT1 chimeric transcription factor. The prognosis for DSRCT is poor, and major advances in...
7.
Tien J, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, et al.
Cell Rep Med
. 2024 Oct;
5(10):101758.
PMID: 39368479
Biallelic loss of cyclin-dependent kinase 12 (CDK12) defines a metastatic castration-resistant prostate cancer (mCRPC) subtype. It remains unclear, however, whether CDK12 loss drives prostate cancer (PCa) development or uncovers pharmacologic...
8.
Alexander J, Schipper K, Nash S, Brough R, Kemp H, Iacovacci J, et al.
Br J Cancer
. 2024 Apr;
130(11):1828-1840.
PMID: 38600325
Background: Invasive Lobular Carcinoma (ILC) is a morphologically distinct breast cancer subtype that represents up to 15% of all breast cancers. Compared to Invasive Breast Carcinoma of No Special Type...
9.
Tien J, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, et al.
bioRxiv
. 2024 Apr;
PMID: 38562774
Biallelic loss of cyclin-dependent kinase 12 () defines a unique molecular subtype of metastatic castration-resistant prostate cancer (mCRPC). It remains unclear, however, whether loss is sufficient to drive prostate cancer...
10.
Baxter J, Brough R, Krastev D, Song F, Sridhar S, Gulati A, et al.
Mol Oncol
. 2023 Oct;
18(2):369-385.
PMID: 37866880
The F-box and WD repeat domain containing 7 (FBXW7) tumour suppressor gene encodes a substrate-recognition subunit of Skp, cullin, F-box (SCF)-containing complexes. The tumour-suppressive role of FBXW7 is ascribed to...